BlackRock: Teva Pharmaceutical Industries TEVA Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 2511 M | Venta |
63,419,932
-474,369
| -0.7% | -USD 17 M | 0.04% | 365 |
|
|
2026
Q2 | USD 2165 M | Venta |
63,894,301
-1,242,163
| -2% | -USD 41.4 M | 0.03% | 423 |
|
|
2026
Q1 | USD 1962 M | Compra |
65,136,464
+6,833,776
| +12% | +USD 220 M | 0.03% | 423 |
|
|
2025
Q4 | USD 1820 M | Compra |
58,302,688
+500,280
| +0.9% | +USD 12.3 M | 0.03% | 441 |
|
|
2025
Q3 | USD 1168 M | Compra |
57,802,408
+3,484,026
| +6% | +USD 61.2 M | 0.02% | 612 |
|
|
2025
Q2 | USD 910 M | Compra |
54,318,382
+2,094,489
| +4% | +USD 33.8 M | 0.02% | 689 |
|
|
2025
Q1 | USD 803 M | Compra |
52,223,893
+1,640,067
| +3% | +USD 29.3 M | 0.02% | 731 |
|
|
2024
Q4 | USD 1115 M | Compra |
50,583,826
+6,783,663
| +15% | +USD 123 M | 0.02% | 581 |
|
|
2024
Q3 | USD 789 M | Compra |
43,800,163
+812,381
| +2% | +USD 14.2 M | 0.02% | 767 |
|
|
2024
Q2 | USD 699 M | Venta |
42,987,782
-716,619
| -2% | -USD 11 M | 0.02% | 792 |
|
|
2024
Q1 | USD 617 M | Compra |
43,704,401
+2,039,540
| +5% | +USD 25.7 M | 0.01% | 885 |
|
|
2023
Q4 | USD 435 M | Compra |
41,664,861
+881,566
| +2% | +USD 8.23 M | 0.01% | 1116 |
|
|
2023
Q3 | USD 416 M | Compra |
40,783,295
+493,488
| +1% | +USD 4.6 M | 0.01% | 1029 |
|
|
2023
Q2 | USD 303 M | Compra |
40,289,807
+123,426
| +0.3% | +USD 1 M | 0.01% | 1280 |
|
|
2023
Q1 | USD 355 M | Venta |
40,166,381
-190,344
| -0.5% | -USD 1.88 M | 0.01% | 1149 |
|
|
2022
Q4 | USD 368 M | Venta |
40,356,725
-1,310,529
| -3% | -USD 11.4 M | 0.01% | 1092 |
|
|
2022
Q3 | USD 336 M | Venta |
41,667,254
-1,410,349
| -3% | -USD 12.5 M | 0.01% | 1092 |
|
|
2022
Q2 | USD 324 M | Compra |
43,077,603
+1,428,887
| +3% | +USD 12.4 M | 0.01% | 1171 |
|
|
2022
Q1 | USD 391 M | Compra |
41,648,716
+1,494,814
| +4% | +USD 12.5 M | 0.01% | 1159 |
|
|
2021
Q4 | USD 322 M | Venta |
40,153,902
-387,943
| -1% | -USD 3.5 M | 0.01% | 1373 |
|
|
2021
Q3 | USD 395 M | Compra |
40,541,845
+785,802
| +2% | +USD 7.36 M | 0.01% | 1178 |
|
|
2021
Q2 | USD 394 M | Venta |
39,756,043
-2,228,410
| -5% | -USD 23.6 M | 0.01% | 1231 |
|
|
2021
Q1 | USD 484 M | Compra |
41,984,453
+4,748,989
| +13% | +USD 54.5 M | 0.01% | 1036 |
|
|
2020
Q4 | USD 359 M | Venta |
37,235,464
-772,165
| -2% | -USD 7.4 M | 0.01% | 1147 |
|
|
2020
Q3 | USD 342 M | Compra |
38,007,629
+388,509
| +1% | +USD 4.11 M | 0.01% | 981 |
|
|
2020
Q2 | USD 464 M | Venta |
37,619,120
-117,187
| -0.3% | -USD 1.33 M | 0.02% | 766 |
|
|
2020
Q1 | USD 339 M | Compra |
37,736,307
+1,671,984
| +5% | +USD 17.1 M | 0.02% | 814 |
|
|
2019
Q4 | USD 353 M | Compra |
36,064,323
+526,979
| +1% | +USD 4.7 M | 0.01% | 1069 |
|
|
2019
Q3 | USD 244 M | Compra |
35,537,344
+578,947
| +2% | +USD 4.44 M | 0.01% | 1258 |
|
|
2019
Q2 | USD 323 M | Compra |
34,958,397
+1,175,800
| +3% | +USD 14.2 M | 0.01% | 1076 |
|
|
2019
Q1 | USD 530 M | Compra |
33,782,597
+42,498
| +0.1% | +USD 749 k | 0.02% | 694 |
|
|
2018
Q4 | USD 520 M | Compra |
33,740,099
+658,864
| +2% | +USD 13.5 M | 0.03% | 632 |
|
|
2018
Q3 | USD 713 M | Compra |
33,081,235
+1,122,592
| +4% | +USD 26.1 M | 0.03% | 560 |
|
|
2018
Q2 | USD 777 M | Compra |
31,958,643
+3,043,358
| +11% | +USD 62.1 M | 0.04% | 502 |
|
|
2018
Q1 | USD 494 M | Venta |
28,915,285
-905,961
| -3% | -USD 17.7 M | 0.02% | 713 |
|
|
2017
Q4 | USD 565 M | Compra |
29,821,246
+611,815
| +2% | +USD 9.2 M | 0.03% | 644 |
|
|
2017
Q3 | USD 514 M | Compra |
29,209,431
+1,719,511
| +6% | +USD 38.7 M | 0.03% | 646 |
|
|
2017
Q2 | USD 913 M | Venta |
27,489,920
-299,228
| -1% | -USD 9.26 M | 0.05% | 391 |
|
|
2017
Q1 | USD 892 M | Compra |
27,789,148
+26,296,961
| +1,762% | +USD 897 M | 0.05% | 391 |
|
|
2016
Q4 | USD 54.1 M | Compra |
1,492,187
+988,954
| +197% | +USD 39.5 M | 0.08% | 295 |
|
|
2016
Q3 | USD 23.2 M | Venta |
503,233
-67,972
| -12% | -USD 3.55 M | 0.03% | 512 |
|
|
2016
Q2 | USD 28.7 M | Venta |
571,205
-77,799
| -12% | -USD 4.14 M | 0.04% | 438 |
|
|
2016
Q1 | USD 34.7 M | Compra |
649,004
+14,609
| +2% | +USD 857 k | 0.06% | 369 |
|
|
2015
Q4 | USD 41.6 M | Venta |
634,395
-114,685
| -15% | -USD 7.09 M | 0.06% | 346 |
|
|
2015
Q3 | USD 42.3 M | Venta |
749,080
-107,153
| -13% | -USD 6.95 M | 0.07% | 316 |
|
|
2015
Q2 | USD 50.6 M | Compra |
856,233
+49,312
| +6% | +USD 3.04 M | 0.08% | 287 |
|
|
2015
Q1 | USD 50.3 M | Compra |
806,921
+244,983
| +44% | +USD 14.2 M | 0.07% | 305 |
|
|
2014
Q4 | USD 32.3 M | Compra |
561,938
+51,242
| +10% | +USD 2.85 M | 0.05% | 408 |
|
|
2014
Q3 | USD 27.4 M | Compra |
510,696
+330,955
| +184% | +USD 17.5 M | 0.04% | 431 |
|
|
2014
Q2 | USD 9.42 M | Compra |
179,741
+1,813
| +1% | +USD 92.7 k | 0.01% | 695 |
|
|
2014
Q1 | USD 9.4 M | Compra |
+177,928
| Nuevas | +USD 8.22 M | 0.02% | 688 |
|
Otros fondos que tienen TEVA en su portafolio
Posición de BlackRock en TEVA: resumen de T3 2026
BlackRock redujo su participación en Teva Pharmaceutical Industries (TEVA) en 0.74% durante T3 2026, al vender acciones por un valor estimado de USD 17 M y quedarse con 63,419,932 acciones valuadas en USD 2511 M. La posición representa 0.04% del portafolio y ocupa el puesto #365.
BlackRock reportó por primera vez una posición en TEVA en T1 2014 y desde entonces la ha mantenido en 51 trimestres. Al cierre de T3 2026, 598 fondos que sigue Wall St. Rank mantienen una posición en TEVA.
- Al cierre de T3 2026, BlackRock tenía 63,419,932 acciones de Teva Pharmaceutical Industries con un valor de USD 2511 M.
- BlackRock vendió 474,369 acciones de Teva Pharmaceutical Industries en T3 2026, por un valor estimado de USD 17 M.
- Teva Pharmaceutical Industries representó el 0.04% del portafolio de BlackRock en T3 2026 y fue su posición número 365.
- BlackRock reportó por primera vez una posición en Teva Pharmaceutical Industries en T1 2014 y desde entonces la ha mantenido en 51 trimestres.
- Al cierre de T3 2026, 598 fondos que sigue Wall St. Rank tenían Teva Pharmaceutical Industries en su portafolio.
Según el informe 13F de BlackRock correspondiente a T3 2026, presentado el 13 nov 2026.